Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.69 |
| ▸ | CA1 | P00915 | 13/20 | 0.69 |
| ▸ | CA5A | P35218 | 8/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 8/20 | 0.69 |
| ▸ | CA9 | Q16790 | 7/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.69 |
| ▸ | CA3 | P07451 | 3/20 | 0.69 |
| ▸ | CA4 | P22748 | 3/20 | 0.69 |
| ▸ | CA6 | P23280 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734123 | 1.00 | CA2 (0.69) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL3743205 | 0.91 | CA2 (0.68) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL3743198 | 0.91 | CA2 (0.68) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL13012579 | 0.91 | CA2 (0.65) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL13042269 | 0.90 | CA2 (0.70) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL3727950 | 0.88 | CA2 (0.69) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL3727945 | 0.88 | CA2 (0.69) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL13042268 | 0.85 | CA2 (0.67) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL3746304 | 0.85 | CA2 (0.74) | CA2CA1CA5ACA5BCA9 | |
| SCHEMBL3746307 | 0.85 | CA2 (0.74) | CA2CA1CA5ACA5BCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-05-14 | — | — | US | claimed |
| US-8354092-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2468734-A1 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | Siemens Medical Solutions USA, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7829063-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | CA9, CA4, CA13 | CA2 9/4885CA1 5/4885CA5A 12/4885 |
| US-20090123372-A1 | DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY | CA9, CA4, CA13 | CA2 9/4885CA1 5/4885CA5A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.